Emergent BioSolutions (EBS) Cash & Current Investments (2010 - 2026)

Emergent BioSolutions' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $161.5 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 5.69% year-over-year to $161.5 million; the TTM figure through Mar 2026 stood at $161.5 million (up 5.69% YoY), while the FY2025 annual figure was $209.1 million, up 98.01% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $161.5 million, down from $209.1 million in the prior quarter.
• The five-year high for Cash & Current Investments was $642.6 million in Q4 2022, with the low at $71.0 million in Q2 2024.
• The 5-year median for Cash & Current Investments is $161.5 million (2026), against an average of $226.6 million.
• The sharpest annual moves came in 2023 and 2025: Cash & Current Investments sank 82.62% in 2023, then surged 281.69% in 2025.
• Emergent BioSolutions' Cash & Current Investments stood at $642.6 million in 2022, then tumbled by 82.62% to $111.7 million in 2023, then retreated by 5.46% to $105.6 million in 2024, then soared by 98.01% to $209.1 million in 2025, then retreated by 22.76% to $161.5 million in 2026.
• Business Quant data shows EBS's Cash & Current Investments at $161.5 million in Q1 2026, $209.1 million in Q4 2025, and $249.2 million in Q3 2025.